1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-amine | 913568-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-amine
• 英文别名: 1-[[5-chloro-2-(2-methylpropoxy)phenyl]methyl]-5-methylpyrazol-3-amine
• CAS: 913568-03-3
• 化学式: C₁₅H₂₀ClN₃O
• 分子量: 293.796
• InChiKey: LNYGFYMZPCLUNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-amine 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.75h， 生成 N-[1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-yl]-4-(3,4-dihydro-2H-pyrrol-5-yl)benzamide
  参考文献：
  名称：

  WO2006/114313

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(trimethylsilyl)ethyl [1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-yl]carbamate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以92%的产率得到1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-amine
  参考文献：
  名称：

  Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists

  摘要：

  We describe the discovery of a series of pyrazole amide EP1 receptor antagonists with good aqueous solubility and CNS penetration. In order to achieve solubility we investigated the incorporation of a basic group in the region of the molecule previously occupied by a carboxylic acid, which was known to be a key element of the pharmacophore. This study led to the identification of compounds such as 4h, 4j and 10b which demonstrated brain-to-blood ratios of 0.8: 1-2.0: 1 in addition to good solubility and metabolic stability. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.118

文献信息

• [EN] SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS<br/>[FR] 1,6-NAPHTYRIDINES SUBSTITUÉES EN VUE D'UNE UTILISATION EN TANT QU'INHIBITEURS DE SCD
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009056556A1

  公开（公告）日：2009-05-07

  The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

  本发明涉及公式（I）的取代四氢萘啶（THN）化合物及其盐，含有它们的药物组合物以及它们在医学上的用途。具体而言，该发明涉及用于抑制SCD活性的化合物。
• PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS
  申请人：Conway Elizabeth Ann

  公开号：US20090239845A1

  公开（公告）日：2009-09-24

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R 1 , R 2a , R 2b , R 10 , R 11 and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中Z、R1、R2a、R2b、R10、R11和Rx的定义如规范所述，制备这种化合物的过程，包含这种化合物的药物组合物以及这种化合物在医学上的用途。
• Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy
  作者：Adrian Hall、Andy Billinton、Susan H. Brown、Nicholas M. Clayton、Anita Chowdhury、Gerard M.P. Giblin、Paul Goldsmith、Thomas G. Hayhow、David N. Hurst、Ian R. Kilford、Alan Naylor、Barry Passingham、Lisa Winyard

  DOI：10.1016/j.bmcl.2008.04.018

  日期：2008.6

  Replacement of the carboxylic acid group in a series of previously described methylene-linked pyrazole EP1 receptor antagonists led to the discovery of amide, reversed amide and carbamate derivatives. Two compounds, 10a and 10b, were identified as brain penetrant compounds and both demonstrated efficacy in the CFA model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.
• [EN] PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS<br/>[FR] COMPOSES DE PYRAZOLE UTILISES COMME LIGANDS DES RECEPTEURS DE LA PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2006114313A1

  公开（公告）日：2006-11-02

  [EN] Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R¹ ,R^2a, R^2b, R¹⁰, R¹¹ and R^x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
  [FR] L'invention concerne des composés de formule (I) ou un dérivé pharmaceutiquement acceptable de ces composés. Dans cette formule Z, R¹, R^2a, R^2b, R¹⁰, R¹¹ et R^x sont tels que définis dans la description. L'invention concerne également un procédé de préparation de ces composés, des compositions pharmaceutiques renfermant ces composés ainsi que l'utilisation desdits composés dans un médicament.
• WO2006/114313
  申请人：——

  公开号：——

  公开（公告）日：——